Apremilast for the treatment of refractory erythema multiforme

The research study is being conducted to help physicians understand if apremilast, an oral medication, is effective in treating recurrent oral erythema multiforme (EM). Study consists of four research study visits (weeks 0,6. 12, 24, 36) and completion of a daily treatment diary during the 24 week tratment period. Week 36 is a follow-up visit to access for safety and can be in person or by phone if subject cannot report to clinic Key eligibility criteria includes male and females age 18-89 years old with a diagnosis of oral, genital, or cutaneous erythema multiforme.

You may be eligible for this study if you meet the following criteria:

• Conditions: Medical Research
• Age: 99 years or below
• Gender: All